Although higher levels of this hormone have been associated with an increased risk of cardiovascular diseases, insulin resistance, arterial hypertension, and obesity in a number of studies, there is no consensus on parathyroid hormone as a biomarker of MetS yet. This evidence concerns the gene PTH and metabolic syndrome.